Wondering how best to approach unresectable inflammatory breast cancer that didn’t respond to neoadjuvant chemo? Here is a multi-institutional French experience> for 18 women receiving pre-operative radiation. The median dose was 50 Gy in 25 fractions with only 3 (17%) receiving a boost to gross disease. Roughly half received concurrent chemo with either a platinum (n=3), capecitabine (n=3), or 5FU (n=4). Two-thirds (n=12) proceeded to surgery as planned, and this was associated with a longer survival time. Median overall survival was 19 months. While locoregional control was maintained in a majority of patients (n=11), most (n=13) developed rapid metastatic progression with an overall median time to distant disease of 5 months—not surprising for a group with disease proven refractory to first-line systemic therapy. | Rogé, Pract Radiat Oncol 2023
